Background: Maternal plasma and/or serum levels of anti-HPA-1a at delivery were compared to neonatal platelet (PLT) counts.
Study Design And Methods: Samples from HPA-1bb women who gave birth to children with thrombocytopenia or had anamnestic information about a previous child with neonatal alloimmune thrombocytopenia (NAIT) were collected at delivery. A modified monoclonal antibody immobilization of PLT antigen method was used for quantification of anti-HPA-1a.
Results: The anti-HPA-1a level in women with severely thrombocytopenic children was higher than the corresponding level in mothers of children born with moderate thrombocytopenia or normal PLT counts.
Conclusion: Our data show a significant correlation between maternal anti-HPA-1a level and the neonatal PLT count and indicate strongly that this may be a reliable predictive measure for NAIT. Suitable test systems for quantitative measurements of anti-HPA-1a must be developed and evaluated for this particular purpose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1537-2995.2007.01063.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Placenta-associated biomarkers and pregnancy outcome in HPA-1a alloimmunization: A prospective cohort study.
Placenta
December 2024
Women's Health and Perinatology Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway; Department of Obstetrics and Gynecology, University Hospital of North Norway, Tromsø, Norway. Electronic address:
Introduction: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) results from parental incompatibility in human platelet antigens (HPA) and subsequent maternal sensitization. The HPA-1a epitope is also expressed on placental tissue. Chronic placental inflammation and lower birth weight is observed more often in HPA-1a alloimmunized pregnancies, suggesting a placental component in the pathophysiology of FNAIT.
View Article and Find Full Text PDFDoes anti-HPA-1a affect birthweight in fetal and neonatal alloimmune thrombocytopenia?
Pediatr Blood Cancer
April 2024
Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA.
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) ensues from parental incompatibility for platelet alloantigens with maternal sensitization. HPA-1a/1b incompatibility is the most common cause of FNAIT in Caucasians. Placental villitis and lower birthweight in FNAIT suggest anti-HPA-1a may have effects beyond inducing thrombocytopenia.
View Article and Find Full Text PDFWhat's with the boys? Lower birth weight in boys from HPA-1a alloimmunized pregnancies - New insights from a large prospective screening study in Poland.
J Reprod Immunol
December 2023
Department of Gynecology and Obstetrics, University Hospital of North Norway, Tromsø, Norway; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway. Electronic address:
Fetomaternal incompatibility in human platelet antigens (HPAs) can cause maternal alloimmunization, which in turn may lead to thrombocytopenia with or without intracranial hemorrhage (ICH) in the fetus or newborn. Retrospective studies suggest that boys from alloimmunized mothers may have higher risk of ICH and lower birth weight than girls. The objective of this study was to assess how maternal HPA-1a alloimmunization, sex of the neonate and birth weight relates in a large prospective cohort.
View Article and Find Full Text PDFABO Incompatibility between the Mother and Fetus Does Not Protect against Anti-Human Platelet Antigen-1a Immunization by Pregnancy.
J Clin Med
November 2022
Institute for Clinical Immunology, Transfusion Medicine and Hemostasis, Justus-Liebig-University, Langhansstr. 7, 35392 Giessen, Germany.
(1) Background: ABO blood group incompatibility between the mother and fetus protects against anti-D immunization by pregnancy. The possible role of ABO incompatibility in protecting against anti-human platelet antigen-1a immunization is unclear. (2) Methods: This study retrospectively screened 817 families (mother-father-neonate trios) of suspected fetal and neonatal alloimmune thrombocytopenia for inclusion.
View Article and Find Full Text PDFFc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets.
Haematologica
October 2022
Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam.
Approximately 20% of patients receiving multiple platelet transfusions develop platelet alloantibodies, which can be directed against human leukocyte antigens (HLA) and, to a lesser extent, against human platelet antigens (HPA). These antibodies can lead to the rapid clearance of donor platelets, presumably through IgG-Fc receptor (FcγR)-mediated phagocytosis or via complement activation, resulting in platelet refractoriness. Strikingly, not all patients with anti-HLA or -HPA antibodies develop platelet refractoriness upon unmatched platelet transfusions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!